Technology
Health
Biotechnology

Intra-Cellular Therapies

$12.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-1.17%) Today
-$0.15 (-1.17%) Today

Why Robinhood?

You can buy or sell ITCI and other stocks, options, ETFs, and crypto commission-free!

About

Intra-Cellular Therapies Inc. Common Stock, also called Intra-Cellular Therapies, is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Read More Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.

Employees
73
Headquarters
New York, New York
Founded
2013
Market Cap
703.76M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
358.92K
High Today
$13.00
Low Today
$12.56
Open Price
$12.87
Volume
27.24K
52 Week High
$23.78
52 Week Low
$10.21

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2013 IPO
US

News

MarketBeatMar 2

Stock Price, News, & Analysis for Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipol...

4
Simply Wall StFeb 27

Does Intra-Cellular Therapies, Inc.’s (NASDAQ:ITCI) CEO Salary Reflect Performance?

Sharon Mates has been the CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) since 2013. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that the business demonstrates. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to consider the appropriateness of CEO pay levels. See our latest analysis for Intra-Cellular Therapies How Does Sharon M...

59
The Motley FoolFeb 27

Intra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript

Intra-Cellular Therapies Inc (NASDAQ:ITCI) Q4 2018 Earnings Conference Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, ladies and gentlemen, and welcome to the Intra-Cellular Therapies Fourth Quarter and Full Year Ended December 31st 2018 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later there will be a question-and-answer session and instructions will follow at that time. ...

44

Earnings

-$0.91
-$0.74
-$0.58
-$0.41
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.